Crestor AstraZeneca - Treatment for Hypercholesterolemia
Crestor is a HMG-CoA reductase inhibitor approved as an adjunct to diet for the treatment of various lipid disorders including primary hypercholesterolemia, mixed dyslipidemia and isolated hypertriglyceridemia.Posted: August 2003
Related articles
- FDA Approves Crestor to Reduce Stroke, Heart Attack Risk - February 9, 2010
- U.S. Food and Drug Administration Approves Crestor for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia - October 16, 2009
- Crestor Approved for Primary Dysbetalipoproteinemia - November 6, 2008
- Crestor Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol - November 9, 2007
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
